gsk presentation, page-2

re: gsk working on ?intravenous relenza http://www.marketwatch.com/News/Story/Story.aspx?guid=%7BF4606E83%2D71F9%2D4D58%2DAFD6%2D4F589FA422C6%7D&dist=newsfinder&siteid=google&keyword=
Last Update: 11:56 AM ET Mar 30, 2006
(extract)
David Stout, GlaxoSmithKline's president of pharmaceutical operations, said the company is continuing to look at other delivery methods for its inhaled antiviral Relenza, which governments have been stockpiling along with Roche Holding AG's (RHHBY) Tamiflu in preparation for a flu pandemic.
"We are continuing to look at other forms, but this is a difficult molecule that is not easily absorbed in oral form," Stout said. "Our inhaled form of Relenza should be in sufficient quantity to meet current demand."
At the time of its fourth-quarter earnings, GlaxoSmithKline said it expected to produce 15 million doses of the drug in 2006.